Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mekinist
Marketing
Novartis' targeted cancer combo wins tumor-agnostic FDA nod
The FDA has granted an accelerated approval to Tafinlar and Mekinist for any advanced solid tumors with BRAF V600E mutation.
Angus Liu
Jun 23, 2022 8:15am
Novartis on the hook for $178M, maybe more, in patent case
Jul 23, 2021 6:30am
NICE clears Pierre Fabre's targeted melanoma combo
Jan 21, 2019 10:09am
Novartis melanoma combo wins thumbs-up from NICE
Sep 18, 2018 10:32am
Europe follows FDA suit with approval spree this week
Aug 31, 2018 9:50am
Array scores FDA nod for Braftovi, Mektovi melanoma combo
Jun 27, 2018 3:18pm
